Latest Director Resignation News

Galileo Mining’s latest drilling at Norseman confirms significant palladium, platinum, and gold mineralisation over a 10km strike, underpinning plans for follow-up resource testing. The company remains well-capitalised to advance exploration.

Johns Lyng Group has officially been acquired by Sherwood BidCo, controlled by Pacific Equity Partners, with shareholders receiving $4.00 per share or equity in the new entity. The company will be delisted from the ASX on October 24, marking a new chapter under private ownership.

Equity Story Group has raised $650,000 through a strategic convertible loan led by new Non-Executive Chair Alex Brinkmeyer, signaling a pivot into property funds management. The company also announced significant board changes, including the appointment of David Nolan as Managing Director.

Platinum Asset Management has finalized its merger with L1 Capital, issuing over 1.65 billion new shares and announcing a rebrand to L1 Group Limited alongside significant board changes and share escrow arrangements.

Dalrymple Bay Infrastructure has appointed CEO Michael Riches as Managing Director, coinciding with the resignation of two non-executive directors following a significant shareholder sell-down.

PYC Therapeutics has restructured its Board and executive team to steer the company through pivotal clinical milestones expected by the end of 2027. The changes signal a strategic push toward late-stage development of its RNA-based drug candidates.

Golden State Mining has raised $1.5 million through a strategic share placement to fund its gold exploration projects and potential acquisitions, alongside notable board changes signaling a new chapter for the company.

RooLife Group Ltd reported a sharp 51% revenue decline to $4.62 million and a 31% increase in net loss to $2.76 million for FY2025, as it pivots towards higher-margin sectors including renewable energy and global social commerce.

Tissue Repair Ltd reported a 27.3% revenue increase to $3.22 million for FY25, driven by new distribution deals and regulatory progress, while continuing to invest heavily in clinical trials and manufacturing scale-up, resulting in a $4.24 million loss.

Atomo Diagnostics reported a 27% reduction in net loss to AUD 4.97 million for FY25, alongside a 7% revenue dip to AUD 3.79 million, driven by stronger margins and cost controls. The company also secured a significant US distribution contract through partner Lumos Diagnostics, positioning it for growth.

Bapcor Limited reported a decline in FY25 pro-forma net profit after tax by 8.4%, alongside a successful $170 million debt refinancing extending maturities to 2029-2031. The company declared a fully franked final dividend and announced significant board and executive changes.

Regal Investment Fund reported a sharp 78% drop in operating profit for FY25 but maintained steady performance slightly above the RBA Cash Rate. The fund bolstered its position with a $104 million capital raise and extended its on-market buy-back program through mid-2026.